MD-Level Note: Steroid Dosing in Nephrotic Syndrome
 |
| checking oedema in nephrotic syndrome |
1. Standard (First Episode) Nephrotic Syndrome
Guideline Reference:
-
Nelson Textbook of Pediatrics (22nd ed., Ch. 494, p. 2570)
Dose:
Prednisolone 2 mg/kg/day (maximum 60 mg/day) for 6 weeks, followed by
1.5 mg/kg on alternate days (maximum 40 mg) for next 6 weeks.
Rationale:
-
Earlier protocols (e.g., 4+4 week or 8-week total) are less effective.
-
Prolonged 12-week regimen (6+6) gives fewer relapses.
Practical Example 1:
A 20 kg child presents with first episode NS.
-
Daily dose: 2 mg/kg = 40 mg daily × 6 weeks.
-
Then alternate-day: 1.5 mg/kg = 30 mg on alternate days × 6 weeks.
-
Total course: 12 weeks.
Avoid: tapering below alternate day dose before completion of 12 weeks — increases relapse.
2. Relapsing Nephrotic Syndrome
a. Infrequent Relapser
-
<2 relapses in 6 months or <3 in 1 year.
Dose:
Prednisolone 2 mg/kg/day until remission (urine protein nil/trace × 3 days),
then 1.5 mg/kg on alternate days for 4 weeks, then stop.
Example:
Child relapses after 5 months remission → give daily 2 mg/kg till protein nil ×3 days → shift to 1.5 mg/kg AD ×4 weeks → stop.
b. Frequent Relapser
-
≥2 relapses in 6 months or ≥4 in 12 months.
Dose:
Same as above for each relapse, but consider tapering or steroid-sparing agent.
Maintenance (if steroid-only used):
Alternate day 0.5–0.7 mg/kg prednisolone for 3–6 months.
Example:
If child relapses every 2 months — after inducing remission, maintain on 0.5 mg/kg AD for 6 months to break cycle.
c. Steroid-Dependent Nephrotic Syndrome (SDNS)
-
Relapse during tapering or within 2 weeks of stopping steroids.
Strategy 1: Low-dose alternate-day steroids
Maintain remission with 0.3–0.5 mg/kg AD for 6–12 months.
Strategy 2: Add steroid-sparing agent
Cyclophosphamide, levamisole, MMF, or calcineurin inhibitor depending on toxicity and previous exposure.
Example:
A 7-year-old develops relapse each time dose falls below 0.5 mg/kg AD → maintain at 0.5 mg/kg AD × 6 months; if Cushingoid, add levamisole.
d. Steroid-Resistant Nephrotic Syndrome (SRNS)
-
No remission after 6 weeks of daily 2 mg/kg prednisolone.
Confirm compliance, dose accuracy, and rule out secondary NS before labeling SRNS.
Protocol:
Continue same dose for total 6–8 weeks before biopsy and calcineurin inhibitor introduction.
Example:
A 6-year-old on pred 2 mg/kg × 6 weeks still 3+ protein — if compliance ensured, classify as SRNS, proceed to biopsy.
3. Partial Responders or Slow Responders
If urine protein reduces but not nil after 6 weeks →
continue full dose 2 mg/kg/day for additional 2 weeks before deciding resistance.
4. Relapse While on Alternate-Day Therapy
Switch to 2 mg/kg/day until remission × 3 days,
then back to alternate-day baseline dose for 4 weeks.
5. Relapse While on Daily Steroid (e.g., during infection)
Do not increase dose; continue same daily dose until infection settles.
After remission, taper normally.
6. Special Scenarios
a. Grossly Edematous Child
-
Use IV methylprednisolone (10–15 mg/kg/day × 3 days) if poor oral absorption suspected, then switch to oral 2 mg/kg/day.
-
Confirm no hypovolemia before diuretics.
b. Infantile Nephrotic Syndrome (<1 yr)
-
Usually genetic; steroid trial limited: 2 mg/kg/day × 6 weeks, but if no response by 4 weeks, stop (to avoid toxicity).
c. Secondary NS (e.g., lupus, infection-related)
-
Dosing guided by underlying disease.
-
Lupus NS: 2 mg/kg/day (max 60 mg) × 4 weeks + taper; or IV methylpred pulses.
7. Tapering Protocols – Practical Pearls
Avoid abrupt stop:
Always taper after alternate-day phase, not during daily phase.
Example – Extended taper for high-risk relapser:
After 6+6 weeks:
-
Reduce to 1 mg/kg AD × 2 weeks
-
Then 0.5 mg/kg AD × 2 weeks
-
Then stop.
Taper traps:
| Mistake | Consequence |
|---|---|
| Stopping abruptly after remission | Rapid relapse |
| Reducing to daily low-dose steroid | Loss of HPA rhythm |
| Using every 3rd day dosing | Relapse risk ↑ |
8. Toxicity Prevention
| Complication | Prevention |
|---|---|
| Cushingoid features | Prefer alternate-day dosing after remission |
| Growth retardation | AD dosing, Vitamin D & calcium |
| Infections | Live vaccines contraindicated during high-dose |
| Hypertension | Salt restriction, monitor BP weekly |
| Cataract | Yearly ophthalmic review |
9. Transition to Steroid-Sparing Agents (for practice)
| Indication | Next Step |
|---|---|
| ≥2 toxic relapses or dependence | Levamisole 2.5 mg/kg AD |
| SDNS with toxicity | Cyclophosphamide 2 mg/kg/day × 12 weeks |
| FRNS with poor tolerance | MMF 600 mg/m² BD |
| Calcineurin inhibitor use | Tacrolimus 0.05–0.1 mg/kg/day in 2 doses |
10. Practical MD-Level Scenarios & Solutions
| Clinical Scenario | Correct Steroid Plan | Explanation |
|---|---|---|
| Relapse during alternate-day 0.5 mg/kg | Switch to 2 mg/kg/day until remission; resume baseline dose 4 weeks | AD dose insufficient; needs induction again |
| 3rd relapse in 3 months, cushingoid | Induce remission, then add levamisole; maintain on 0.3 mg/kg AD | To reduce toxicity |
| First episode remission after 4 weeks | Continue daily to complete 6 weeks; then AD 6 weeks | Early remission doesn’t mean early taper |
| Proteinuria returns within 7 days of stopping steroids | Steroid-dependent → restart 2 mg/kg/day → maintain 0.5 mg/kg AD × 6 months | Defines dependence |
| SRNS after 8 weeks | Proceed biopsy, add tacrolimus + low-dose pred 0.5 mg/kg AD | Steroid resistance confirmed |
| Child unable to take orally due to vomiting | IV methylpred 10 mg/kg/day × 3 days → switch to oral | Ensures systemic delivery |
| Child develops varicella while on 2 mg/kg/day | Stop steroids temporarily; IV acyclovir; restart after lesion crusting | Prevent fatal dissemination |
11. Key Pharmacologic Notes
-
Bioavailability: Prednisolone preferred (not deflazacort for initial induction).
-
Equivalent doses: 5 mg prednisolone = 4 mg methylpred = 0.75 mg dexamethasone.
-
Morning dosing preferable to preserve circadian rhythm.
12. Reference Sources
-
Kliegman RM, Nelson Textbook of Pediatrics, 22nd ed., Elsevier, 2023.
-
Indian Pediatrics Nephrology Group, Consensus Statement on Management of Nephrotic Syndrome, 2021.
-
IPNA Clinical Practice Recommendations for Idiopathic NS, 2020.
-
Avner ED et al., Pediatric Nephrology, 8th ed. (RPS, 2022).
